Burris, Howard A <br/><br/>
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.  [electronic resource] 

 -  Molecular cancer therapeutics  Aug 2012 
 - 1820-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-11-0997  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Female<br/>Humans<br/>Indazoles<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome